Trials / Terminated
TerminatedNCT02337387
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 2 Formulations of Blosozumab in Postmenopausal Women
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. This study will last approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to starting the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Blosozumab | Administered SC |
| OTHER | Placebo | Administered SC |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2015-01-13
- Last updated
- 2019-01-22
- Results posted
- 2019-01-22
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02337387. Inclusion in this directory is not an endorsement.